Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study
Summary: Background: Kidney damage in COVID-19 patients has been of special concern. The association of acute kidney injury (AKI) with post-acute kidney function among COVID-19 survivors was not sufficiently elucidated. Methods: An ambidirectional cohort study was conducted with enrollment of COVID...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-02-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396422000068 |
| _version_ | 1819261418858348544 |
|---|---|
| author | Xiaoying Gu Lixue Huang Dan Cui Yeming Wang Yimin Wang Jiuyang Xu Lianhan Shang Guohui Fan Bin Cao |
| author_facet | Xiaoying Gu Lixue Huang Dan Cui Yeming Wang Yimin Wang Jiuyang Xu Lianhan Shang Guohui Fan Bin Cao |
| author_sort | Xiaoying Gu |
| collection | DOAJ |
| description | Summary: Background: Kidney damage in COVID-19 patients has been of special concern. The association of acute kidney injury (AKI) with post-acute kidney function among COVID-19 survivors was not sufficiently elucidated. Methods: An ambidirectional cohort study was conducted with enrollment of COVID-19 survivors discharged from hospital between Jan 7, and May 29, 2020. Study participants were invited to follow-up visits at 6 and 12 months after symptom onset. The primary outcome was percentage of estimated glomerular filtration rate (eGFR) decreased from acute phase (between symptom onset and hospital discharge) to follow-up, and secondary outcome was reduced renal function at follow-up. Findings: In total, 1,734 study participants were included in this study. Median follow-up duration was 342.0 days (IQR, 223.0-358.0) after symptom onset. After multivariable adjustment, percentage of eGFR decreased from acute phase to follow-up was 8.30% (95% CI, 5.99-10.61) higher among AKI participants than those without AKI at acute phase. Participants with AKI had an odds ratio (OR) of 4.60 (95% CI, 2.10-10.08) for reduced renal function at follow-up. The percentage of eGFR decreased for participants with AKI stage 1, stage 2, and stage 3 was 6.02% (95% CI, 3.48-8.57), 15.99% (95% CI, 10.77-21.22), and 17.79% (95% CI, 9.14-26.43) higher compared with those without AKI, respectively. Interpretation: AKI at acute phase of COVID-19 was closely related to the longitudinal decline and post-acute status of kidney function at nearly one-year after symptom onset. Earlier and more intense follow-up strategies on kidney function management could be beneficial to COVID-19 survivors. Funding: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS 2020-I2M-CoV19-005, 2018-I2M-1-003, and 2020-I2M-2-013); National Natural Science Foundation of China (82041011); National Key Research and Development Program of China (2018YFC1200102); Major Projects of National Science and Technology on New Drug Creation and Development of Pulmonary Tuberculosis (2020ZX09201001). |
| first_indexed | 2024-12-23T19:41:29Z |
| format | Article |
| id | doaj.art-fb7b909459c140d3a95005cb18433ff1 |
| institution | Directory Open Access Journal |
| issn | 2352-3964 |
| language | English |
| last_indexed | 2024-12-23T19:41:29Z |
| publishDate | 2022-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj.art-fb7b909459c140d3a95005cb18433ff12022-12-21T17:33:40ZengElsevierEBioMedicine2352-39642022-02-0176103817Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort studyXiaoying Gu0Lixue Huang1Dan Cui2Yeming Wang3Yimin Wang4Jiuyang Xu5Lianhan Shang6Guohui Fan7Bin Cao8Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China; National Center for Respiratory Medicine, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China; Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China; National Center for Respiratory Medicine, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China; Department of Pulmonary and Critical Care Medicine, Capital Medical University, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China; National Center for Respiratory Medicine, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China; Harbin Medical University, Harbin, ChinaDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China; National Center for Respiratory Medicine, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China; Department of Pulmonary and Critical Care Medicine, Capital Medical University, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China; National Center for Respiratory Medicine, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China; National Center for Respiratory Medicine, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China; National Center for Respiratory Medicine, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China; National Center for Respiratory Medicine, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China; Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China; National Center for Respiratory Medicine, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China; Department of Pulmonary and Critical Care Medicine, Capital Medical University, Beijing, China; Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China; Corresponding author.Summary: Background: Kidney damage in COVID-19 patients has been of special concern. The association of acute kidney injury (AKI) with post-acute kidney function among COVID-19 survivors was not sufficiently elucidated. Methods: An ambidirectional cohort study was conducted with enrollment of COVID-19 survivors discharged from hospital between Jan 7, and May 29, 2020. Study participants were invited to follow-up visits at 6 and 12 months after symptom onset. The primary outcome was percentage of estimated glomerular filtration rate (eGFR) decreased from acute phase (between symptom onset and hospital discharge) to follow-up, and secondary outcome was reduced renal function at follow-up. Findings: In total, 1,734 study participants were included in this study. Median follow-up duration was 342.0 days (IQR, 223.0-358.0) after symptom onset. After multivariable adjustment, percentage of eGFR decreased from acute phase to follow-up was 8.30% (95% CI, 5.99-10.61) higher among AKI participants than those without AKI at acute phase. Participants with AKI had an odds ratio (OR) of 4.60 (95% CI, 2.10-10.08) for reduced renal function at follow-up. The percentage of eGFR decreased for participants with AKI stage 1, stage 2, and stage 3 was 6.02% (95% CI, 3.48-8.57), 15.99% (95% CI, 10.77-21.22), and 17.79% (95% CI, 9.14-26.43) higher compared with those without AKI, respectively. Interpretation: AKI at acute phase of COVID-19 was closely related to the longitudinal decline and post-acute status of kidney function at nearly one-year after symptom onset. Earlier and more intense follow-up strategies on kidney function management could be beneficial to COVID-19 survivors. Funding: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS 2020-I2M-CoV19-005, 2018-I2M-1-003, and 2020-I2M-2-013); National Natural Science Foundation of China (82041011); National Key Research and Development Program of China (2018YFC1200102); Major Projects of National Science and Technology on New Drug Creation and Development of Pulmonary Tuberculosis (2020ZX09201001).http://www.sciencedirect.com/science/article/pii/S2352396422000068COVID-19Acute kidney injuryPost-acuteRenal function |
| spellingShingle | Xiaoying Gu Lixue Huang Dan Cui Yeming Wang Yimin Wang Jiuyang Xu Lianhan Shang Guohui Fan Bin Cao Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study EBioMedicine COVID-19 Acute kidney injury Post-acute Renal function |
| title | Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study |
| title_full | Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study |
| title_fullStr | Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study |
| title_full_unstemmed | Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study |
| title_short | Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study |
| title_sort | association of acute kidney injury with 1 year outcome of kidney function in hospital survivors with covid 19 a cohort study |
| topic | COVID-19 Acute kidney injury Post-acute Renal function |
| url | http://www.sciencedirect.com/science/article/pii/S2352396422000068 |
| work_keys_str_mv | AT xiaoyinggu associationofacutekidneyinjurywith1yearoutcomeofkidneyfunctioninhospitalsurvivorswithcovid19acohortstudy AT lixuehuang associationofacutekidneyinjurywith1yearoutcomeofkidneyfunctioninhospitalsurvivorswithcovid19acohortstudy AT dancui associationofacutekidneyinjurywith1yearoutcomeofkidneyfunctioninhospitalsurvivorswithcovid19acohortstudy AT yemingwang associationofacutekidneyinjurywith1yearoutcomeofkidneyfunctioninhospitalsurvivorswithcovid19acohortstudy AT yiminwang associationofacutekidneyinjurywith1yearoutcomeofkidneyfunctioninhospitalsurvivorswithcovid19acohortstudy AT jiuyangxu associationofacutekidneyinjurywith1yearoutcomeofkidneyfunctioninhospitalsurvivorswithcovid19acohortstudy AT lianhanshang associationofacutekidneyinjurywith1yearoutcomeofkidneyfunctioninhospitalsurvivorswithcovid19acohortstudy AT guohuifan associationofacutekidneyinjurywith1yearoutcomeofkidneyfunctioninhospitalsurvivorswithcovid19acohortstudy AT bincao associationofacutekidneyinjurywith1yearoutcomeofkidneyfunctioninhospitalsurvivorswithcovid19acohortstudy |